All In Biotech

NDA 019028 · Solventum

Peridex

Chlorhexidine Gluconate · Dental

Priority review

Last checked: Nov 19, 2026Latest source record: Apr 9, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Aug 13, 1986

Approved uses

1

Original approval plus efficacy supplements

Registered trials

551

112 Phase 3, 30 recruiting

FAERS reports

8,740

7,269 serious, 2,883 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 1, 2024.

INDICATION: Peridex is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. Peridex has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 13, 1986 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
  • PERIDEX · CHLORHEXIDINE GLUCONATE 0.12% · SOLUTION, DENTAL · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Chlorhexidine Gluconate" as an intervention, any sponsor and status, largest first.

All 551 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue2,010
  • joint swelling1,745
  • rash1,726
  • pain1,715
  • hypersensitivity1,672
  • impaired healing1,668
  • arthralgia1,624
  • weight increased1,624
  • folliculitis1,623
  • dyspnoea1,605
  • stomatitis1,602
  • glossodynia1,545

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200441
200534
200638
200763
2008119
2009128
2010187
2011207
2012203
201395
2014110
2015193
2016314
2017330
2018375
2019366
2020486
2021757
2022666
2023547
20241,349
20251,578
2026553

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 596 on PubMed

Sponsor: Solventum

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.